Clinical Trial Update: Ritlecitinib in CTCL [Phase 2]

View source ↗

Summary

A Phase 2 trial of ritlecitinib for cutaneous T-cell lymphoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Mycosis Fungoides
• Sézary Syndrome

Drugs mentioned

• Ritlecitinib (ritlecitinib)

Snippet

Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: CTCL, Mycosis Fungoides | Phase 2 | Status: TERMINATED